Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc. is a pharmaceutical company specializing in the development of long-acting injectable drug products, primarily targeting central nervous system (CNS) disorders and chronic diseases. Founded in 2016 and headquartered in Taichung, Taiwan, the company uses an advanced delivery platform to create formulations that steadily release active ingredients over periods ranging from several weeks to months. Its product pipeline includes treatments for opioid use disorder, alcohol use disorder, chronic pain, treatment-resistant depression, Parkinson’s disease, and schizophrenia. Notable formulations such as sustained-release buprenorphine, apomorphine, ketamine, naltrexone, and other injectables address unmet medical needs in both Asian and international markets. By leveraging the 505(b)(2) regulatory pathway, Alar Pharmaceuticals seeks to improve medication adherence and reduce treatment burdens for chronic conditions. The company has garnered recognition for its distinctive approach—emphasizing reduced injection volumes, low viscosity solutions, and sustained drug release profiles that aim to minimize side effects and maximize therapeutic benefit. This positions Alar Pharmaceuticals as an innovative participant in the specialty drug and biotechnology sector, addressing significant challenges in mental health and addiction treatment.